The AmoyDx PLC panel using FCPs can be an alternative method for analyzing oncogenic driver alterations in patients with NSCLC for whom sufficient amount of tissue specimen for the NGS assay cannot be obtained. Here, HSPG2 is linked to non-small cell lung carcinoma.